/INNPF

INNPF Stock - INNOCAN PHARMA Corp

Q: What is the analyst price target for INNPF?

Analyst price target information is not currently available for INNPF.

Q: What is INNPF's market cap?

Market capitalization information is not currently available for INNPF.

Healthcare|Drug Manufacturers - Specialty & Generic|OTC

$7.23+5.39%

+$0.37 (+5.39%) • Dec 5

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

HOLD

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

100

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+10.0%upside

Target: $7.95

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for INNPF

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2020

FY2021

FY2022

FY2023

FY2024

← Swipe to see more →

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta-0.04

52W High$14.26

52W Low$6.86

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2024	FY2023	FY2022	FY2021	FY2020
Revenue	$29.44M	$13.66M	$2.56M	$196,000	$8,000
Gross Profit	$26.19M	$11.98M	$2.11M	$121,000	$3,000
Gross Margin	89.0%	87.7%	82.3%	61.7%	37.5%
Operating Income	$-1,247,000	$3.80M	$-6,266,000	$-7,480,000	$-4,725,000
Net Income	$-1,834,000	$-4,700,000	$-3,764,000	$-10,047,000	$-9,953,000
Net Margin	-6.2%	-34.4%	-147.1%	-5126.0%	-124412.5%
EPS	$-0.42	$-1.19	$-0.98	$-2.91	$-3.99

Company Overview

InnoCan Pharma Corporation, a pharmaceutical company, focuses on the development of various drug delivery platforms combining cannabidiol (CBD) with other pharmaceutical ingredients in the United States, Poland, France, and internationally. The company engages in the research and development of COVID-19 and other condition treatment by using CBD loaded exosomes; and CBD loaded liposomes. Its product includes CBD eye serum, CBD face oil, CBD face cream, CBD facial serum, CBD sleeping mask, CBD recovery lotion, and the Relief & Go spray. The company is also involved in the commercialization and sale of branded CBD integrated pharmaceutical and topical treatment products. InnoCan Pharma Corporation was incorporated in 2018 and is headquartered in Calgary, Canada.

Visit Website

Frequently Asked Questions about INNPF

What is INNPF's current stock price?

INNOCAN PHARMA Corp (INNPF) is currently trading at $7.23 per share. The stock has moved +5.39% today.

What is the analyst price target for INNPF?

No analyst price targets are currently available for this stock.

What sector is INNOCAN PHARMA Corp in?

INNOCAN PHARMA Corp operates in the Healthcare sector, specifically within the Drug Manufacturers - Specialty & Generic industry. The company is traded on the OTC exchange.

What is INNPF's market cap?

INNOCAN PHARMA Corp has a market capitalization of $0.03 billion, making it a small-cap company.

Does INNPF pay dividends?

No, INNOCAN PHARMA Corp does not currently pay a dividend to shareholders.